FINLAND - Faron Pharmaceuticals Oy , a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, today announces the release of further insights from its Phase. | April 25, 2023
Faron Pharmaceuticals Ltd on Monday said further data from its Phase I/II MATINS study of bexmarilimab has indicated the efficacy and safety of the immunotherapy in solid tumours.
The Turku,. | April 24, 2023
<iframe src=https://www.youtube.com/embed/bwMF6GsdB6Q></iframe>Faron Pharmaceuticals Limited chief financial officer James O Brien speaks to Proactive on his second day in the new. | April 6, 2023
Faron Pharmaceuticals Ltd on Wednesday said it has appointed James O Brien as its new chief financial officer, effective from Monday next week, succeeding Toni Hanninen.
The Turku, Finland-based. | March 29, 2023